Beximco PharmaceuticalsBXMPY 93 PS Ratio is 0.00 as of Jul. 06, 2026. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 71.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Beximco Pharmaceuticals's share price is $0.00.
Beximco Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.98. Hence, Beximco Pharmaceuticals's PS Ratio for today is 0.00.
Warning Sign:
Beximco Pharmaceuticals PLC stock PS Ratio (=1.2) is close to 2-year high of 1.21.
The historical rank and industry rank for Beximco Pharmaceuticals's PS Ratio or its related term are showing as below:
BXMPY'
s PS Ratio Range Over the Past 10 Years
Min: 0.67 Med: 1.73 Max: 5.73
Current: 1.2
During the past 13 years, Beximco Pharmaceuticals's highest PS Ratio was 5.73. The lowest was 0.67. And the median was 1.73.
BXMPY's PS Ratio is ranked better than 71.85% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs BXMPY: 1.20
During the past 13 years, Beximco Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 24.70% per year. The lowest was -12.30% per year. And the median was 13.50% per year.
Back to Basics: PS Ratio
Beximco Pharmaceuticals (OTCPK:BXMPY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Beximco Pharmaceuticals's Share Price of today is $0.00. Beximco Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Beximco Pharmaceuticals (BXMPY) has a PS Ratio of 0.00 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beximco Pharmaceuticals and its competitors. Over the past decade, Beximco Pharmaceuticals' PS Ratio has ranged from 0.67 to 5.73. According to the industry distribution chart, Beximco Pharmaceuticals ranks #268 out of 952 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is Beximco Pharmaceuticals' PS Ratio too high?
Beximco Pharmaceuticals' current PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 5.73. Based on the distribution chart, Beximco Pharmaceuticals ranks #268 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #268 out of 952 companies for PS Ratio. This puts Beximco Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 2.32. Historically, Beximco Pharmaceuticals' own PS Ratio has ranged from 0.67 to 5.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current PS Ratio is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 